oru.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis
Steno Diabetes Center, Gentofte, Denmark.
Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, McGill University, Montréal, QC, Canada; Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, QC, Canada.
Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
Steno Diabetes Center, Gentofte, Denmark.
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Translational Psychiatry, ISSN 2158-3188, E-ISSN 2158-3188, Vol. 6, nr 11, artikel-id e951Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. In this study, we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients. We applied comprehensive metabolomics to investigate serum metabolite profiles in a prospective study setting in 36 first-episode psychosis patients during the first year of the antipsychotic treatment and 19 controls. While corroborating several earlier findings when comparing cases and controls and the effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with increased levels of triacylglycerols with low carbon number and double-bond count at baseline, that is, lipids known to be associated with increased liver fat. Our study suggests that metabolite profiles may be used to identify the psychotic patients most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the antipsychotic-induced weight gain.

Ort, förlag, år, upplaga, sidor
London. United Kingdom: Nature Publishing Group, 2016. Vol. 6, nr 11, artikel-id e951
Nationell ämneskategori
Psykiatri
Forskningsämne
Psykiatri
Identifikatorer
URN: urn:nbn:se:oru:diva-53599DOI: 10.1038/tp.2016.222ISI: 000392133200004PubMedID: 27845774OAI: oai:DiVA.org:oru-53599DiVA, id: diva2:1048638
Anmärkning

Funding Agency:

European Union  602478

Tillgänglig från: 2016-11-21 Skapad: 2016-11-21 Senast uppdaterad: 2017-11-29Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Hyötyläinen, Tuulia

Sök vidare i DiVA

Av författaren/redaktören
Hyötyläinen, Tuulia
Av organisationen
Institutionen för naturvetenskap och teknik
I samma tidskrift
Translational Psychiatry
Psykiatri

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 196 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf